Calcivis Secures $5 Million in Series A Funding to Revolutionize Tooth Decay Treatment

We are thrilled to announce that CALCIVIS has successfully raised $5 million in funding, a significant milestone that propels our mission to revolutionize dental care and preventive dentistry. As an innovative dental biologic and device manufacturer headquartered in Edinburgh, Scotland, with a robust presence in the US, CALCIVIS is on a relentless quest to transform the way tooth decay is assessed and managed. Our state-of-the-art technology, now FDA-approved, provides real-time, chairside assessment of enamel demineralization—the “Holy Grail” of cariology. This groundbreaking capability offers clinicians critical insights into the caries disease process, an area that has long lacked comprehensive evaluation tools. The funding will be instrumental in scaling our operations, enhancing product distribution, and furthering our research and development efforts. Our goal is to reduce reliance on painful, complicated surgical interventions by fostering a preventive approach to dental health. By facilitating early decision-making and strengthening communication between clinicians and patients, we aim to boost compliance with oral health guidelines and improve patient consent for necessary treatments. This not only leads to better clinical outcomes but also enhances the overall patient experience. As we embark on this exciting journey, we are committed to empowering dentists and their patients with the information and tools they need to manage dental health effectively and innovatively. Together, we can create a healthier future for dental care.